🚨🫁 Sevabertinib has been approved in Japan for the treatment of patients with HER2-mutant non–small cell lung cancer (NSCLC). 🧬📊
Read more ➡️ www.onclive.com/view/sevaber...
#LungCancer #NSCLC #HER2 #HER2Mutation #TargetedTherapy #PrecisionOncology #ThoracicOncology #Oncology
Read more ➡️ www.onclive.com/view/sevaber...
#LungCancer #NSCLC #HER2 #HER2Mutation #TargetedTherapy #PrecisionOncology #ThoracicOncology #Oncology
Sevabertinib Approved in Japan for HER2-Mutant Non–Small Cell Lung Cancer | OncLive
The MHLW approval covers all lines of therapy, including first-line use, in unresectable advanced or recurrent HER2-mutant NSCLC.
www.onclive.com
August 24, 2026 at 6:08 PM
🚨🫁 Sevabertinib has been approved in Japan for the treatment of patients with HER2-mutant non–small cell lung cancer (NSCLC). 🧬📊
Read more ➡️ www.onclive.com/view/sevaber...
#LungCancer #NSCLC #HER2 #HER2Mutation #TargetedTherapy #PrecisionOncology #ThoracicOncology #Oncology
Read more ➡️ www.onclive.com/view/sevaber...
#LungCancer #NSCLC #HER2 #HER2Mutation #TargetedTherapy #PrecisionOncology #ThoracicOncology #Oncology